**Supplementary Table 3:** Associations between statin use and prostate cancer aggressiveness, overall and stratified by race and additionally adjusted for education, income and family history of prostate cancer.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **All** | | **Caucasian** | | **African American** | |
|  | **n, cases (aggressive)** | **OR\* (95% CI)** | **n, cases (aggressive)** | **OR\* (95% CI)** | **n, cases (aggressive)** | **OR\* (95% CI)** |
| **Statin use** |  |  |  |  |  |  |
| No use | 1,024 (200) | 1.00 (ref) | 514 (87) | 1.00 (ref) | 510 (113) | 1.00 (ref) |
| Use | 610 (92) | 0.71 (0.53-0.94) | 346 (43) | 0.59 (0.39-0.91) | 264 (49) | 0.81 (0.54-1.21) |
| **Statin dosea** |  |  |  |  |  |  |
| No use | 1,024 (200) | 1.00 (ref) | 514 (87) | 1.00 (ref) | 510 (113) | 1.00 (ref) |
| Low/normal | 264 (37) | 0.66 (0.44-0.99) | 155 (20) | 0.56 (0.32-0.98) | 109 (17) | 0.71 (0.39-1.27) |
| High | 346 (55) | 0.74 (0.53-1.05) | 191 (23) | 0.63 (0.37-1.05) | 155 (32) | 0.87 (0.54-1.40) |
| **Statin typeb** |  |  |  |  |  |  |
| No use | 1,024 (200) | 1.00 (ref) | 514 (87) | 1.00 (ref) | 510 (113) | 1.00 (ref) |
| Hydrophilic | 109 (12) | 0.47 (0.25-0.90) | 64 (6) | 0.41 (0.16-1.04) | 45 (6) | 0.46 (0.18-1.19) |
| Lipophilic | 500 (80) | 0.77 (0.57-1.04) | 282 (37) | 0.64 (0.41-1.00) | 218 (43) | 0.90 (0.59-1.38) |

**\***adjusted for age, race (except for analyses stratified by race), center, BMI, cholesterol intake, percent saturated fat intake, smoking status, PSA screening frequency, education level, annual household income, family history of prostate cancer

**a**low/normal dose≤20mg simvastatin or equivalent; high dose>20mg simvastatin or equivalent

**b**Hydrophilic=rosuvastatin, pravastatin; Lipophilic=atorvastatin, simvastatin, lovastatin, fluvastatin